Лечение пациента с диссеминированной герминогенной опухолью яичка на фоне терминальной хронической болезни почек, требующей проведения гемодиализа

Среди онкологических пациентов существует когорта больных с терминальной хронической болезнью почек (ХБП), развившейся вследствие различных причин и требующей назначения гемодиализа. Проведение противоопухолевого лекарственного лечения при данном сопутствующем заболевании возможно, однако требует выбора наиболее оптимальных модифицированных режимов химиотерапии (ХТ) с целью достижения максимальной эффективности и минимизации токсичности лечения. В данном клиническом случае мы описываем наш лечебный подход для пациента, находящегося на гемодиализе, с метастатической несеминомной герминогенной опухолью (ГО) яичка неблагоприятного прогноза по классификации International Germ Cell Cancer Collaborative Group (IGCCCG). Нами был проведен анализ литературных данных, отражающих применение различных лекарственных препаратов и режимов ХТ, используемых для лечения ГО у пациентов с ХБП.

1. Alifrangis С., Sharma A., Chowdhury S., et al. Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. EurJ Cancer 2022;164:105-113. https://doi.Org/10.1016/j.ejca.2020.08.031

2. Bajorin D.F., Sarosdy M.F., Pfister D.G., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;ll(4):598-606. https://doi.Org/10.1200/JCO.1993.ll.4.598

3. Horwich A., Sleijfer D.T., Fossa S.D., et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15(5):1844-52. https://doi.org/10.1200/JC0.1997.15.5.1844

4. Feldman D.R., Bosl G.J., Sheinfeld J., et al. Medical treatment of advanced testicular cancer. JAMA 2008;299(6):672-84. https://doi.Org/10.1001/jama.299.6.672. PMID: 18270356

5. Hanna N.H., Einhorn L.H. Testicular cancer-discoveries and updates. N Engl J Med 2014;371(21):2005-16. https://doi.org/10.1056/NEJMral407550. Erratum in: N EnglJ Med 2014;371(24):2342. PMID: 25409373

6. Feldman D.R. State-of-the-Art Management of Germ Cell Tumors. Am Soc Clin Oncol Educ Book 2018;38:319-323. https://doi.org/10.1200/EDBK_201139

7. Gillessen S., Sauve N., Collette L., et al. International Germ Cell Cancer Classification Update Consortium. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol 2021;39(14):1563—1574. https://doi.org/10.1200/JCO.20.03296. Erratum in: J Clin Oncol 2022;40(20):2283. PMID: 33822655

8. Fizazi K., Pagliaro L., Laplanche A., et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumors (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 2014;15:1442-1450. https://doi.org/10.1016/S1470-2045(14)70490-5

9. Janus N., Launay-Vacher V., Yhyss A., et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 2013;24(2):501—507. https://doi.org/10.1093/annonc/mds344

10. Bokemeyer C., Kohrmann O., Tischler J., et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol 1996;7(10):1015—21. https://doi.org/10.1093/oxfordjournals.annonc.a010493

11. Moore K.J., Snow S., Wood L.A. Delivering Chemotherapy to a Metastatic Poor Risk Testicular Cancer Patient on Hemodialysis. Curr Oncol 2022;29(3):1808-1812. https://doi.org/10.3390/curroncol29030148

12. Gorodetsky R., Vexler A., Bar-Khaim Y., et al. Plasma platinum elimination in a hemodialysis patient treated with cisplatin. Ther Drug Monit 1995;17(2):203—6. https://doi.org/10.1097/00007691-199504000-00018

13. Ikeda K., Terashima M., Kawamura H., et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol 1998;28(3):168-75. https://doi.Org/10.1093/jjco/28.3.168

14. Janus N., Thariat J., Boulanger H., et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010;21(7):1395—1403. https://doi.org/10.1093/annonc/mdp598

15. Crooke S.T., Luft F., Broughton A., et al. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 1977;39(4):1430—4. https://doi.org/10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-v

16. Latcha S., Maki R.G., Schwartz G.K., et al. Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis. Sarcoma 2009;2009:575629. https://doi.org/10.1155/2009/575629

17. Hirakawa H., Nakashima Ch., Nakamura T., et al. Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report. J Med Case Rep 2017;ll(l):43 https://doi.org/10.1186/sl3256-017-1213-7

18. Froehner M., Passauer J., Schuler U., et al. Successful chemotherapy for advanced nonseminomatous germ-cell tumor in a patient undergoing chronic hemodialysis. J Clin Oncol 2007;25(10):1282-4. https://doi.org/10.1200/JCO.2006.09.9549

19. Tryakin A., Fedyanin M., Bulanov A., et al. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.J Cancer Res Clin Oncol 2018;144(9):1817-1823. https://doi.org/10.1007/s00432-018-2695-4

20. Williams S.D., Birch R., Einhorn L.H., et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N EnglJ Med 1987;316(23):1435-40. https://doi.org/10.1056/NEJM198706043162302

21. Crooke S.T., Luft F., Broughton A., et al. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 1977;39(4):1430—4. https://doi.org/10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-v

22. R de Wit., Stoter G., Sleijfer D.T., et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998;78(6):828-32. https://doi.org/10.1038/bjc,1998.587

23. Feldman D., Hu J., Srinivas S., et al. Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate-or poor-risk germ cell tumors (GCT). J Clin Oncol 2018;36(15 suppl):4508-4508. https://doi.org/10.1200/JCO.2018.36.15_suppl.4508

24. Collette L., Sylvester R.J., Stenning S.P., et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999;91(10):839-46. https://doi.org/10.1093/jnci/91.10.839

25. Клинические рекомендации. Герминогенные опухоли у мужчин, 2020. Доступно по: https://cr.minzdrav.gov.ru/recomend/584_l